Asset Details
Do you wish to reserve the book?
Development of allogeneic iPS cell‐based therapy: from bench to bedside
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Development of allogeneic iPS cell‐based therapy: from bench to bedside
Do you wish to request the book?
Development of allogeneic iPS cell‐based therapy: from bench to bedside
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Development of allogeneic iPS cell‐based therapy: from bench to bedside
2023
Overview
This commentary provides a brief overview of the steps necessary for the generation of an induced pluripotent stem (iPS) cell‐derived clinical grade product. This process requires extensive, proper documentation as well as a thoughtful and systematic optimization of the manufacturing methods to ensure maintenance of the key biological features of the product, compliance with current good manufacturing practices (cGMP), and most importantly patient safety. The scale‐up and optimization also ideally include the identification of efficient and cost‐effective purification/isolation and expansion of the target cell population.
Graphical Abstract
This Commentary discusses the production process of an induced pluripotent stem cell‐derived clinical grade therapeutic – from bench to bedside.
Publisher
Nature Publishing Group UK,EMBO Press,John Wiley and Sons Inc,Springer Nature
